News & Alerts
-
Aug- 2023 -23 August
Former Pharmacy President Pleads Guilty in $32 Million Medicare, Tricare Scheme
A former president of a pharmacy enterprise has entered a guilty plea for his involvement in a complex plot aimed…
Read More » -
23 August
Pregnant Women’s New Tool: FDA Greenlights Abrysvo Vaccine to Safeguard Newborns from RSV
In a major development, the U.S. Food and Drug Administration (FDA) has granted approval for the Abrysvo vaccine, potentially equipping…
Read More » -
23 August
FDA Warns Against Use of Contaminated Eye Drops: Dr. Berne’s and LightEyez Products Under Scrutiny
The U.S. Food and Drug Administration (FDA) has issued a warning to consumers regarding the use of certain eye drop…
Read More » -
22 August
South African Court Backs Pharmacy-Initiated HIV Treatment
In a landmark decision this week, the Pretoria High Court has given the green light to the South African Pharmacy…
Read More » -
22 August
U.S. Patients Paying Up to 10 Times More for Ozempic, Rybelsus, Mounjaro, and Wegovy – KFF
In a startling revelation, a comparative analysis has shown that U.S. patients are paying up to 10 times more for…
Read More » -
21 August
FDA Halts Gilead’s Magrolimab Blood Cancer Trials
In a recent development, Gilead Sciences has faced a setback as the U.S. health regulator, the Food and Drug Administration…
Read More » -
21 August
FDA Greenlights New Eylea Formulation for Wet AMD, DME, and DR
The US Food and Drug Administration (FDA) has granted clearance for the new 8 mg formulation of Eylea (aflibercept), marking…
Read More » -
19 August
Regeneron’s Breakthrough Treatment, Veopoz, Granted FDA Approval for Rare Disease
In a significant development, Regeneron Pharmaceuticals, Inc. has announced the approval of Veopoz™ (pozelimab-bbfg) by the U.S. Food and Drug…
Read More » -
18 August
MSF Challenges GSK’s Contract Clauses for Access to Apretude
Médecins Sans Frontières (MSF), an international medical humanitarian organization, has been diligently working to secure access to ViiV Healthcare’s innovative…
Read More » -
18 August
Tukysa’s Trial Success Spurs Roche’s Kadcyla and Pfizer’s $43B Acquisition
Pfizer’s strategic move to acquire Seagen for $43 billion is primarily motivated by the Seattle biotech’s advantage in the field…
Read More »